BIO-crucial International’s biometric identity solutions now support Home windows Terminal Solutions and Citrix Clients BIO-crucial International, Inc. , a head in finger-structured biometric identification solutions, today announced the growth of its biometric identification solutions to consist of support for Home windows Terminal Solutions Remote Desktop Process , Citrix ICA Customer systems and for Wyse CE terminals tadalafil-espana.com . Application providers will have a simple alternative to what has typically been a complex issue – deploying biometric fingerprint identification on an area customer that accesses applications working on a central server.
.. BG Medication receives US patent for galectin-3 tests to detect heart failure BG Medicine, a lifestyle sciences company centered on the discovery, advancement, and commercialization of novel diagnostics predicated on biomarkers, announced the issuance of U today.S. Patent No. 7,888,137, entitled WAY FOR Identifying a Subject vulnerable to Developing Heart Failing by Determining the amount of Galectin-3 or Thrombospondin-2 to the University of Maastricht. BG Medicine comes with an exclusive license to the issued patent, which concerns galectin-3 testing for folks at an increased risk for heart failing. The patent term expires in 2026. This seminal patent can be an essential step towards our objective of obtaining wide patent insurance for galectin-3 screening in the region of cardiac disease, stated Pieter Muntendam, MD, President and CEO of BG Medication.